Four major medical organizations have issued a formal correction to their joint advisory on nutrition for people using GLP-1 medications. The corrigendum, published in the journal Obesity (Silver Spring), updates the original guidance co-authored by the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society — making dietary best practices for GLP-1 users an active, evolving conversation.
What the Original Advisory Covered
The original joint advisory was designed to address a gap that many GLP-1 users experience firsthand: these medications powerfully reduce appetite and food intake, but eating less doesn't automatically mean eating well. The advisory from these four organizations aimed to outline nutritional priorities — including adequate protein, micronutrient intake, and dietary quality — to help patients on GLP-1 therapy preserve muscle mass and support overall health while losing weight.
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) work in part by slowing gastric emptying and reducing hunger signals in the brain, which can dramatically lower how much a person eats day to day. Without intentional nutritional planning, that reduced food intake can fall short on protein and key vitamins and minerals.
Why a Correction Was Issued
A corrigendum is a formal, peer-reviewed correction to a previously published scientific paper. The issuance of one does not mean the original advisory was fundamentally flawed — corrigenda are a routine part of maintaining accuracy in medical literature, addressing anything from data errors to clarifications of specific recommendations. The source material does not specify which elements of the original advisory were corrected, so patients should consult the updated version of the document directly or ask their care team what changed.
Key takeaway: The joint nutrition advisory for GLP-1 therapy has been formally updated by its publisher. If you're on Ozempic, Wegovy, Mounjaro, or Zepbound, ask your prescriber or a registered dietitian whether the correction affects any dietary guidance you were given.
What This Means for Patients on GLP-1 Medications
For people currently taking a GLP-1 medication, the practical message is straightforward: nutrition guidance in this space is still being refined as clinical experience grows. Key principles that have broad support across obesity medicine include:
- Prioritizing protein at every meal to help protect lean muscle mass during weight loss
- Monitoring micronutrient intake, since eating significantly less food can reduce intake of vitamins and minerals
- Staying hydrated, which can be challenging when appetite and thirst cues are blunted
- Working with a registered dietitian who is familiar with GLP-1 therapy to personalize a nutrition plan
Because the specific content of the correction has not been detailed in the available source material, patients should not assume their current guidance is incorrect — but it is worth confirming with their provider.
What to Watch Next
As GLP-1 medications continue to be prescribed at scale, expect clinical nutrition guidance to keep evolving. The involvement of four prominent organizations — the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society — signals that nutritional support for GLP-1 therapy is being taken seriously at the highest levels of obesity and lifestyle medicine. Updated versions of joint advisories like this one are likely to shape how dietitians and prescribers counsel patients in the coming years.
Frequently Asked Questions
Nutritional guidance for GLP-1 therapy continues to evolve as researchers and clinicians gain more real-world experience with these medications. If you have questions about how the updated advisory might affect your diet or supplement routine, speak with your prescriber or a registered dietitian before making any changes to your plan.
- PubMed peer-reviewed publication, Corrigendum to 'Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society,' Journal: Obesity (Silver Spring)